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concentrated extract made from porcine or bovine ovaries) of ovariectomized or postmenopausal women [13, 14] , and likely described the first rapid effects related to estrogen: "the condition improved immediately after administration of Ovarialsubstanz" [13] . Similar findings were also reported by Landau [15] and Mond [16] .
It was at this time that molecular medicine appeared on the horizon, long before the genetic code was deciphered or medical genetics were known. Already in the early 1890s Canadian physician Sir William Osler at Johns Hopkins University in Baltimore had identified hereditary patterns in families with coronary artery disease [17] , and in 1894 the German pathologist Rudolf Virchow, considered the "father of modern pathology" [18, 19] proposed changing the prevailing dogma in anatomy, pathology and disease development, foreseeing the future of cellular and molecular biology and current modern medicine -concepts that were fully compatible with the observations of early endocrinologists discussed above [13] [14] [15] [16] [17] [18] [19] [20] [21] . Virchow presented his revolutionary views in a lecture presented at the XI International Medical Congress in Rome on March 30 , 1894, which he ended with the following words: "…The idea of the 'sedes morborum', or, as I have designated it, 'the anatomical concept'. It is this thought that governs the physiology and pathology of today. Whether it leads one back to the cells, as it does me, or whether another formula is developed, it will surely remain the concept for the future. And this future will mark the beginning of its chronology in the days of Morgagni. Let him be honoured!." [22] . Ironically, the journal in which Virchow's lecture was published (Berliner Medizinische Wochenschrift) merged with Therapeutische Monatsheft in 1922 to become Klinische Wochenschrift, and in 1995 changed its name to the Journal of Molecular Medicine [23] .
It is worth noting that the chemical identity of steroids and particularly estrogens has only been known for less than a century, work that is largely owed to the American Edward A. Doisy and the German Adolf Butenand (1903 to 1995), both of whom, in 1929, simultaneously discovered estrone [24] [25] [26] [27] . At the time, Butenand was 26, having obtained his PhD only two years earlier in Göttingen with Adolf Windaus (1876 to 1956), the Nobel Laureate in Chemistry in 1928 for the discovery of vitamin D and sterols [28] . By 1935, Butenand had also identified progesterone and testosterone; Doisy later also isolated 17-estradiol and estriol [27, 29, 30] . Of note, both discoverers of estrogens also went on to win a Nobel Prize.
Butenand received the Nobel Prize in Chemistry in 1939, and Doisy was awarded the Nobel Prize in Physiology or Medicine in 1943 [27, 30] .
The first evidence of a receptor for estrogen was presented by Elwood V. Jensen (1920 Jensen ( -2012 in the 1950s [29, 31, 32] ; however, it took 30 more years until the gene sequence of the first nuclear estrogen receptor was cloned [33] [34] [35] . In 2016, the Hungarian-American biologist Clara M. Szego (Figure 1 ) celebrated her 100 th birthday. Fifty years earlier, Szego reported increases in cAMP production following acute exposure to estrogen [36] . In the following years Szego found the uterine cAMP increase to be inhibited by glucocorticoids [37] and  blockers (only if the adrenals were intact) [38] , and also purified an estrogen receptor protein, demonstrating inhibition of its function using antibodies [39] . Ironically, it was again Szego, who in 1977 first reported estrogen receptors in plasma membrane fractions [40] , which she later partially purified and characterized [41, 42] . In the 1980s, the cDNA sequence of first estrogen receptor (today known as ER) was determined [33] [34] [35] , and by the mid 1990s, both the second nuclear estrogen receptor (today known as ER) and an orphan receptor designated GPR30 were cloned [43] [44] [45] [46] [47] [48] [49] [50] . Initially believed to represent a GPCR for cytokines, the function(s) of GPR30 remained elusive until recently. In the following sections, the individual authors will summarize their personal history and perspectives in this field.
GPER in hiding: rapid effects of estrogen

M. Barton
One of the clinical observations for centuries had been that premenopausal women are largely protected from coronary artery disease and its clinical manifestations [51] . I began my work in the field of coronary artery disease and atherosclerosis in 1990 at the Division of Cardiology at Hannover Medical School in Germany, headed by the Swiss physician Paul R. Lichtlen . In the 1960s, Lichtlen had pioneered coronary angiography in Europe at the University of Zürich and moved to Hannover in 1973 [52] . My studies, supported by Andreas Mügge and the cardiothoracic surgeons, were centered around the question of whether estrogen may exert acute vasodilatory effects on human coronary arteries. Human physiology studies had indirectly suggested the existence of rapid effects of estrogen in peripheral veins [53] , but they had not been demonstrated for human arteries. At the time, the identity of endothelium-derived relaxing factor (EDRF) as nitric oxide (NO) had just been discovered [54] [55] [56] , and only one estrogen receptor (today known as ER) had been cloned [33] [34] [35] ; whether this or additional estrogen receptors were involved in the regulation of vascular tone was not known.
During my studies, which took more than three years to complete, it turned out that within minutes, 17-estradiol causes relaxation of human coronary arteries (Figure 2) of both women and men [57] . Results also showed that a 30-minute exposure to 17-estradiol indirectly improved vasodilation by enhancing endothelium-dependent relaxation [58] . At the time Lichtlen invited me to participate in my first scientific meeting, a small «International Workshop on Atherosclerosis» that he organized on October 9-10,1992 in Celle, Germany. Participants included many notable physician-scientists such as Gustav V. Born (b. 1921), Christian C.
Haudenschild, Philippe D. Henry , Helmut Drexler (1951-2009) Elizabeth G. Nabel, David G. Harrison, as well as Peter Ganz, who at the time was also conducting studies on vascular effects of estrogens in humans, which he published in 1994 [59] .
In search of the underlying mechanisms to help explaining the observed rapid vasodilatory response, I came across Clara M. Szego's early studies showing induction of cAMP production following acute estrogen exposure [36] . To investigate whether the observed rapid vascular effects involved any changes in cAMP production, I set up similar experiments human coronary arteries with help from Michaela Kuhn, an expert in cyclic nucleotide biology, demonstrating that within 30 minutes of application -the time required to induce full arterial relaxation -17estradiol increased vascular cAMP content [57] , both observations that could neither be explained by genomic mechanisms [60] , nor by activation of the endothelial Larginine/NO/guanylate cyclase pathway. In the following year, Benita Katzenellenbogen, utilizing intact uterine tissue, also reported rapid increases in cyclic AMP content after a 30minute exposure to 17-estradiol [61] . Two years later, cloning of a second nuclear estrogen receptor was reported and named ER [62, 63] , as was GPR30 [44] , albeit as an orphan receptor without known ligand at the time.
Meanwhile, following the advice of Paul Lichtlen and with his support, I had moved to Switzerland continuing my research in this area and began working on estrogen receptors [64, 65] . In 2002, a young medical student by the name of Matthias Meyer joined my group and we agreed that he would also study acute effects of estrogen on human vascular tissue. Meyer started his research (for which he later received the Medical Faculty's Best Thesis Award at the University of Zürich) and approached me one day, holding a print-out of an article, asking me whether I had seen the paper. It was a article by Eric Prossnitz's group from the University of New Mexico reporting the identification of GPR30 as an intracellular transmembrane estrogenbinding receptor acting through PI3-kinase, thus identifying it as a third bona fide estrogen receptor [66] . I immediately thought back to my own studies from the early 1990s and realized that this receptor might explain part of the acute effects of 17-estradiol on cyclic AMP observed back then, and perhaps also the vascular relaxation. Meyer proposed to also study GPR30 expression in his experiments. He found that human blood vessels indeed express GPR30, which was sensitive to regulation by estrogen. Meyer reported his observations as unpublished data in April 2006 in his first peer-reviewed article [67] . The full data were published in a research report [68] that I dedicated to Paul Lichtlen, who had died in 2005, the same year we had started our work on GPER.
In 2006, I contacted Prossnitz who agreed to share his GPER-specific ligands with us. In addition, I was fortunate to obtain mice lacking the Gper gene (generated by Jan Rosenbaum [69] ) from Debbie Clegg, who was then at the University of Cincinnati, and was also introduced to Cristina and Eugen Brailoiu, experts in calcium biology at Temple University, and physiologist Tom Resta, at UNM. Together, we published a report in January 2009 showing that GPER acts as an intracellular membrane receptor controlling cell proliferation, that it acutely reduces vascular tone and blood pressure, and that its genetic deletion leads to abdominal obesity [70] .
We have since developed a very productive collaboration with Prossnitz and our studiesmost of them performed by Meyer with enormous curiosity and persistenceled to the identification and characterization of multiple new, particularly genomic roles of GPER in cardiovascular function and disease which we will discuss elsewhere in this issue [71] . Looking back, without Paul Lichtlen's mentoring, support, and trust in a young colleague, we might have never known…
Cloning of an orphan GPCR named GPR30
S. Lolait
The initial success in cloning G protein-coupled receptors (GPCR) was based on targeted approaches that relied predominantly upon biochemical purification of the receptor protein or on expression cloning where prior receptor sequence knowledge was not required. With the realization that GPCRs had a topography of 7 transmembrane (TM) domains and displayed varying degrees of conservation between and across GPCR subclasses, homology cloning came to the fore. This was facilitated by PCR and augmented by bioinformatics analysis of various genomes. (Figure 3 ) -one of these was eventually named CMKRL2 (chemokine related receptor like 2) given its closest homology (approx. 30% overall amino acid identity) to chemokine GPCRs, but it did not respond to a battery of chemokines when expressed in cell lines [44] . GPR30 're-emerged' in our lab a few months later in mouse form when I used a similar PCR-based strategy to isolate a novel GPCR cDNA clone (AtT20#9) from a murine AtT20 pituitary tumor cDNA library. Cell lines expressing the corresponding fulllength clone did not respond to the peptide ligands in which I was interested at the time (e.g., corticotropin releasing factor, vasopressin) so the clone went to the back of the freezer.
Parenthetically, we were interested in fast steroid responses in the lab around this time -there were numerous futile attempts to elicit rapid elevations in intracellular Ca 2+ levels in response to estrogen, aldosterone or corticosterone in Xenopus oocytes expressing both the Ca 2+ -sensitive photoprotein aequorin and mRNAs isolated from various tissues and cells. We never tested whether cell lines stably expressing our human or mouse GPR30 clones responded to estrogen.
The cloning of CMKRL2 published in 1996 [44] was closely followed over the next year or so by independent reports of the isolation of the same human orphan GPCR cDNA under various aliases (e.g., CEPR, LyGPR, FEG-1, GPCR-Br [46] [47] [48] [49] [50] ) and a rat homologue GPR41 [45] . The GPR30 designation was adopted [46, 50] following on from the consecutive numbering of previous GPCR orphans reported in the literature. The cloning of most of the GPR30s was based on PCR with degenerate primers to highly conserved TM regions of known GPCRs, using libraries constructed from cDNA or genomic DNA (as most GPCR genes are intronless or contain very few introns in their open reading frame) as a template. One exception was a GPR30 cDNA sequence deposited in GenBank as 'DRY12' (accession number U58828) in mid-1996 that resulted from an effort to expression clone a receptor for 1-antitrypsin-protease complexes (David Perlmutter, personal communication, 2016). In addition, GPCR-Br/GPR30 was obtained by differential screening of an MCF7 breast tumor cell cDNA library with cDNA probes from estrogen receptor (ER)-positive and ER-negative tumor cell lines. This was the first clue that GPR30 might be related to estrogen responsiveness [46] .
The studies noted above showed that the human GPR30 gene maps to chromosome 7 and lacks introns in its protein-coding portion. Its translated DNA sequence (open reading frame) predicts a 375 amino acid protein that has consensus sites for possible post-translational modification (e.g., glycosylation, phosphorylation) and the structural signature of the Class A Rhodopsin-like GPCR subfamily (e.g., it has a 'DRY' amino acid motif at the tail of TM3). It is ubiquitously expressed as a 2-3kb mRNA transcript in brain regions (e.g., hypothalamus and hippocampus) and peripheral tissues such as placenta, prostate, lung, heart, liver and lymphoid tissue, and is particularly abundant in some lymphocyte cell lines (but less so in purified lymphocytes) and vascular endothelial cells subjected to shear stress [49] . Gene expression profiles, useful in the deorphanisation of some GPCRs (e.g., cannabinoid CB1 receptor [72] ), especially when performed in an anatomical context at the cellular level, provided little insight into a possible endogenous GPR30 ligand. I discovered in mid-late 2000, when performing DNA sequence comparisons (NCBI BLAST), that our murine AtT20 and human lymphoblast cDNA clones were species homologues -up until that time I had never compared the two translated protein sequences! To my surprise a study had also reported that GPR30-associated intracellular pathways were activated by estrogen [73] . Given my interest in rapid steroid effects, the irony that I had not tested estrogen on our orphan GPCR clones did not escape me!!
Molecular biology of GPR30 and its rapid effects
To play an integral role in the development of a paradigm-shifting idea built by collegial interaction is truly a rewarding experience. My contribution towards the idea that GPCRs promote pre-genomic signaling by sex steroid hormones was rooted in my postdoctoral work in David Cheresh's lab at Scripps Research Institute. Unbeknownst to me, Eric Prossnitz (also at the early stages of his scientific career) was working at the same time in Charlie Cochrane's group, at his lab bench a mere 10 yards from mine. Although we did not collaborate or interact while at Scripps, both of us were working on structure/function relationships centered upon transmembrane receptors and intracellular signaling. The intersection of our work was not as obvious then as it is now. While my work focused on the molecular basis of bidirectional signaling by integrins [74] [75] [76] , Eric was working on structure-function relationships of chemoattractant receptors of the GPCR superfamily.
My journey towards GPR30 began with my interest in the work by Keith Yamada that described "rapid", pre-genomic intracellular signaling networks activated by integrin occupancy and aggregation [77, 78] By the late 1990s, many laboratories had implicated GPCRs and/or G proteins in estrogenmediated activation of cAMP and other second messengers [79] ; however, the mechanism that linked estrogen to protein kinase signaling was entirely unclear. Robert Lefkowitz [80] , and Axel Ullrich [81] provided a molecular mechanism by which a single GPCR could trigger, in parallel, second messenger and EGFR-mediated signaling pathways through activation of G-and Gdependent signaling mechanisms. Based on these findings, I became intrigued by the idea that an orphan GPCR, whose known ligand had yet-to-be identified, could serve as a singular receptor mechanism capable of activating second messenger and protein kinase pathways.
While earlier investigators evaluating pre-genomic estrogen signaling relied solely on ERpositive cell models, I was keen on including ER-negative breast cancer cell models in our analysis. A colleague of mine at Brown, Raymond Frackelton, an expert in EGFR signaling, was a key contributor to these early experiments and pointed out that human SKBr3 breast cancer cells were negative for ER and its recently cloned homologue ER, at the level of RT-PCR. I remember my surprise, when Jeffrey Quinn from my lab showed me the results that estrogen was capable of promoting EGFR tyrosine phosphorylation in SKBr3 breast cancer cells as well as ER-positive MCF-7 cells. Yet, we observed that the same response was not detected in ERnegative MDA-MB-231 cells despite the fact that EGF stimulation led to potent EGFR activation in these cells. I must have asked Jeff to repeat these experiments at least a dozen times! We were even more surprised that ER antagonists also triggered EGFR activation in SKBr3 cells and these data suggested to us that the mechanism of action was clearly ER-independent.
GPR30 was isolated as a molecular clone by different laboratories and received its orphan designation because its cognate ligand had yet to be identified. We noticed that it was cloned from breast cancer, cardiovascular tissue, brain and other estrogen-responsive tissues [44, [46] [47] [48] [49] [50] . We were particularly interested in the fact that it had been isolated by subtractive cloning from breast cancer lines that displayed differences in their competence for pre-genomic signaling by estrogen [46] , causing us to consider the possibility that GPR30 may serve as an estrogen receptor. A phone call to Ron Weigel resulted in the use of his GPR30 molecular clone in marker rescue experiments to test the concept that GPR30 may trigger G-and Gdependent activation of adenylyl cyclase and EGFR tyrosine kinase activity [73, 79] . Interested in determining whether we could measure specific estrogen binding associated with GPR30, I contacted Peter Thomas, a comparative endocrinologist with expertise in steroid membrane receptor binding. We had a nice telephone conversation and were excited about designing experiments that would test the possibility that GPR30 may provide an evolutionarily conserved ER-independent mechanism of estrogen signaling. Through the use of a traditional radioligand binding assay, Peter and I were able to link estrogen binding activity to GPR30 expression in enriched plasma membrane preparations isolated from tissues derived from both man [82, 83] and fish [84] . Key to the strength of these data was the observation that uncoupling Gs from GPR30 significantly reduced ligand binding [82, 84] . Studies from the Prossnitz lab using an independent approach showed the association of specific GPR30 binding by fluorescentlylabeled estrogen derivatives [66] and that selective synthetic agonists/antagonists discriminate GPR30 from ER [85, 86] , helping to further establish the concept that GPR30 is an estrogen receptor, and leading to its description as an estrogen receptor now known by its IUPHAR functional designate as GPER [87] .
To date, the most vexing part of understanding the molecular mechanism of GPER has been the observation that its expression is commonly, but not exclusively localized to intracellular membranes in many tissues. Endogenous GPER is expressed on the cell surface in certain tissues, including oocytes, pyrimadal neurons and cortical renal epithelia [88] . GPER is not alone in this regard, as many GPCRs show a predominantly intracellular expression pattern and have been shown to function intracellularly [89] , particularly following internalization [90] , but also on nuclear, Golgi apparatus and endoplasmic reticulum membranes [91, 92] . Nevertheless, the mechanisms that limit GPCR surface expression at the plasma membrane also represent a primary means to dictate cellular responsiveness of many GPCRs to their cognate ligands, particularly those that are not membrane permeable in contrast to lipids and steroids. For this reason, studies that investigate the molecular mechanisms that determine the subcellular distribution of GPER are the next critical step in understanding its mechanism of action, and may be vital in developing effective pharmacological agents that target this novel estrogen receptor.
Binding and signal transduction of GPER
P. Thomas
I became interested in nongenomic steroid actions in 1980 when I began investigating the endocrine control of oocyte meiotic maturation in fish. Recent studies in fish and amphibians had indicated that a maturation-inducing steroid (MIS) acts on the oocyte surface through a membrane receptor to induce meiotic maturation by a transcription-independent mechanism [93, 94] . Reynaldo Patino developed a reliable membrane receptor filtration assay for measurement of MIS receptor binding in our laboratory [95] , which proved to be indispensable for our subsequent studies to identify novel steroid receptors. The assay was used to track MIS receptor binding by Yong Zhu during the purification, cloning and characterization of the membrane progestin receptor α (mPRα), which belongs to the progestin adipoQ receptor (PAQR) family, and is the first steroid receptor unrelated to nuclear steroid receptors discovered in vertebrates [33, 34, 35] . Modifications of the receptor assay were later used in our laboratory by Hakan Berg to track androgen binding during purification, cloning and characterization of the novel membrane androgen receptor, ZIP9, a zinc transporter protein belonging to the SLC39A family [36, 37] Fortunately, the lengthy procedures we used to identify mPRα and ZIP9 were not required to identify the novel membrane estrogen receptor (ER) because a candidate, the orphan GPCR, GPR30, had already been identified by Edward Filardo [73] . He had identified GPR30 as a potential membrane ER based on his pioneering research on estrogen stimulation of adenylyl cyclase/cAMP and EGFR/MAPK signaling in GPR30-positive, nuclear estrogen receptor (ER)negative breast cancer cells [73, 79, 96] . We gladly accepted Ed's invitation to participate in a collaborative research effort to determine if human GPR30 is a membrane ER. A 17β-estradiol (E2) binding activity with all the characteristics of a membrane ER was identified on SKBR3 cell membranes, which express GPR30 but lack full-length nuclear ERs, and in ER-null HEK293 cells transfected with GPR30, using our well-characterized receptor assay for croaker membrane ER [82, 97] . Competitive binding studies showed that binding to GPR30 is specific for E2, environmental estrogens, and ER antiestrogens (ICI 182,780, tamoxifen), whereas the potent ER agonist, diethylstilbestrol, and other classes of steroids showed no displacement of [ 3 H]-E2 over a wide range of concentrations [82, 98] .
At about the same time our initial characterization of GPR30 was published, a paper from Eric Prossnitz's research group employing E2 conjugated to a fluorescent label showed that the E2conjugate bound the GPR30 with the characteristics of a membrane ER [66] . Confirmation that GPR30 is a membrane ER by the two research groups working independently provided the impetus for further research on the receptor. However, the cellular localization of GPR30 would remain unresolved as Eric's studies observed GPR30 is expressed predominantly and activated intracellularly [66, 99] , in contrast to our results demonstrating it is activated on the cell surface [82, 83] .
Interestingly, the ER antiestrogens ICI 182,780 and tamoxifen were found to act as GPER agonists, mimicking the E2-induced increase in cAMP production [82] . The finding that several environmental estrogens, including bisphenol A, nonylphenol, genistein, zearalenone, display relatively high binding affinities for GPER and act as agonists to increase cAMP synthesis [98] , provided an early indication that these compounds can disrupt nongenomic estrogen actions through the receptor. Recently, we found that an E2 metabolite, the catecholestrogen 2hydroxy-E2, binds with high affinity to zebrafish GPER and acts and a GPER antagonist, reversing E2 maintenance of oocyte meiotic arrest in this species [100] .
It has been proposed that GPER may also act as an aldosterone receptor based on the observation that GPER expression is involved in aldosterone stimulation of ERK1/2 phosphorylation [101, 102] , although direct evidence that GPER binds aldosterone was lacking.
In detailed binding experiments, we did not detect any specific [ 3 H]-aldosterone binding to plasma membrane fractions of mouse kidneys that have high GPER expression, or to HEK293 cells expressing recombinant GPER, both of which displayed high binding to [ 3 H]-E2 [103] .
Aldosterone and several mineralocorticoid receptor antagonists also did not compete with [ 3 H]-E2 binding to GPER, which suggests that the interactions of aldosterone with GPER do not involve direct binding to the ligand-binding region of the receptor. Consistent with this notion, work by Maggiolini's group has recently shown cross-talk between GPER and MR in mediating the effects of aldosterone [104] .
Recent research in our laboratory by Yefei Pang and others has focused on the characteristics and reproductive functions of GPER in fish oocytes. Despite approximately 450 million years of divergent evolution of human and teleost GPERs, their receptor binding characteristics including steroid specificity are remarkably similar [84, 105] . In addition, the human and fish receptors are directly coupled to the same G protein (Gs) and activate the same signaling pathways (adenylyl cyclase/cAMP and EGFR/MAPK) [105, 106] . These comparative studies suggest the membrane ER activity of GPER is its fundamental, conserved primary physiological function in vertebrates. It is not known, though, whether the reproductive functions of GPER identified in fish are shared by other vertebrates.
Pharmacology and physiology of GPER
Having studied G protein-coupled receptor structure/function relationships and signaling pathways in the context of neutrophil activation by chemoattractants since 1989 [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] , I was immediately intrigued with the idea of a GPCR functioning as an estrogen receptor in 2002 based on the then recent review of GPR30 by Ed Filardo [79] . This work had first been presented to a group of investigators at UNM by Kim Leslie, who was organizing an NCI SPORE application on endometrial cancer. We formed a working group in late 2002 to begin to develop a project to examine the potential contribution of GPR30 to endometrial function and carcinogenesis. Towards that goal, I requested a clone of GPR30 from Ron Weigel (due to his relative geographical proximity), who reported the cloning of GPCR-Br (i.e. GPR30) in 1997 [46] . The original team at UNM included Larry Sklar, with whom I had long been collaborating on chemoattractant GPCR function [123] , as well as the development of high throughput flow cytometry [124] , since our days at the Scripps Research Institute, and Tudor Oprea, an expert in cheminformatics, who had recently arrived from AstraZeneca [125, 126] . Larry Sklar soon introduced me to Jeffrey Arterburn at New Mexico State University, a synthetic organic chemist, who by chance was already working of estrogen derivatives for imaging purposes [127, 128] .
This group of individuals, along with highly talented post-doctoral fellows, Chetana Revankar in my lab, and Cristian Bologa in the Oprea group, formed the basis of the team that initially explored GPER function in cells [66] and soon screened for GPER-selective ligands [85] . It was Chetana Revankar, who showed me our first image of GPR30-RFP expressed in COS7 cells, which revealed a completely unexpected predominantly intracellularly localized GPER (Figure 4) , an observation that would later be confirmed in many, but not all, cell types with antibodies detecting endogenous GPER [66] , and manually carried out the screening of the top 100 estrogen-like compounds (computationally identified by Tudor Oprea from a library of 10,000 compounds at UNM). The GPER-selective compound, later named G-1, was #92 [85] ; one can only wonder how things might have been different had it been #101! In connection with the original Endometrial SPORE application, I was also introduced to Harriet Smith, a gynecologic oncologist at UNM, with whom I would work to examine the prognostic potential of GPER expression in endometrial and ovarian cancers [129, 130] . It is perhaps ironic that our first publication on GPER, describing E2 binding to GPER and differential signaling by GPER and ER, was submitted to Science in August 2004 [66] , within about a week of the paper by Peter Thomas and Ed Filardo, describing similar findings using entirely different approaches [82] .
Recognizing that a fundamental question regarding GPER was its physiological role(s) in health and disease states, I realized that we needed to expand our cell-based studies to animal models, an area in which I was not experienced. So it was with great fortune that I discussed our work with my departmental colleague Helen Hathaway, an expert on the development of the mammary gland and murine models of disease [131] . In 2006, I was contacted by and soon (in 2008) met Matthias Barton at a drug discovery meeting in Dubai, beginning a more than 10-
year collaboration [70, [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] . Various combinations of these individuals (along with superb graduate students, post-docs and technicians) would be central to our studies over the years to demonstrate that 1) GPER-expressing cells exhibited binding of a fluorescent estrogen derivative that colocalized with GPER to intracellular membranes (endoplasmic reticulum and Golgi apparatus) (Arterburn, Sklar, [66]); 2) only cell permeable estrogen derivatives rapidly activate GPER, suggesting intracellular GPER is functionally active (Arterburn, [99] ); 3) GPERselective agonists and antagonists, that do not interact with the classical estrogen receptors, can be identified (Oprea, Sklar, Arterburn, [85, 86, 148, 149] ); 4) GPER can be visualized in vivo through the use of novel radio-imaging agents (Arterburn, [150] [151] [152] [153] [154] [155] ); 5) using murine models, including GPER knockout mice, GPER plays important roles in both breast and endometrial cancer (but not uterine imbibition for example) (Hathaway, [86, [156] [157] [158] ) as well as in metabolism (Hathaway, [159] ) and vascular biology and disease (Barton, [70, 134, (139) (140) (141) (142) (145) (146) (147) 160, 161] ); 6) GPER is prognostic for survival in both endometrial and ovarian cancers (Smith, [129, 130] ) and 7) GPER is critical in aging through its regulation of superoxide production via Nox1 (Barton, [162] ). Our work to understand the roles of GPER in metabolism [163] and vascular biology [71] and the potential clinical benefits of GPER-selective agonists and antagonists [149] are reviewed elsewhere in this special issue. My progress in this field over the years has not only been made possible by these many individuals, as well as gifted graduate students, technicians and post-docs, but also the co-authors of this article. In retrospect, I also believe that my background in GPCR molecular pharmacology provided me with a fresh unbiased viewpoint, influenced little by the dogma of nuclear estrogen receptors, that facilitated much of our progress in the field. As a final thought regarding serendipity in science, it was not until working on GPER for some time that I realized, upon searching for new publications by Ed Filardo in Pubmed, that Ed and I had both been post-docs at Scripps in the early 1990'sin fact in neighboring labs!
Transcriptional regulation by GPER
M. Maggiolini
Working in the years 1998-1999 as a visiting professor in Didier Picard's lab at the Université de Genève, Switzerland, I had my first opportunity to provide novel insights into estrogen receptor (ER)-mediated functions in breast cancer [164, 165] , and subsequently to demonstrate that certain phytoestrogens may elicit stimulatory effects in this malignancy by activating ERs [166, 167] . Further searching for the multifaceted aspects of estrogen signaling, it was intriguing how I came across GPER. Unexpectedly, ER-negative (but GPER-positive) SKBr3 breast cancer cells displayed relevant biological responses upon estrogen/phytoestyrogen exposure [168] . Initially, it was challenging to understand our results in the context of existing paradigms.
However, the initial studies of Filardo's group on GPER helped us to explore new mechanisms, as the silencing of GPER abrogated the effects of the aforementioned compounds [168] . One important aspect of these investigations was that agonist-activated GPER engages the EGFR/MAPK signal transduction pathway resulting in the rapid transcriptional activation of the oncogene c-FOS, which was thereafter used as a molecular sensor of GPER action in other cell contexts such as thyroid and endometrial tumor cells [169, 170] . Working together with Eric Prossnitz (University of New Mexico, USA), we then ascertained that in GPER-and ER-positive ovarian cancer cells, 17β-estradiol and the selective GPER ligand G-1 upregulated several estrogen-responsive genes such as c-FOS, pS2, and cyclins A, D1 and E; in contrast however, progesterone receptor (PR) only responded to E2 [171] . These data, together with the results obtained by silencing experiments and growth assays, suggested that a functional interaction between GPER and ERα may occur when both receptors are expressed in tumor cells [171] .
In the framework of my meaningful and long-standing collaboration with Didier Picard, it was fortuitous that a post-doc (D. Prakash Pandey) from his group came to my lab and, working together with my collaborators, defined the gene signature prompted by estrogenic GPER signaling [172] . Interestingly, gene responses included a first tier of transcription factors including SRF, CREB, and members of the ETS family followed by a second wave of transcription factors such as FOS, JUN, CTGF, EGR1, ATF3, C/EBPd and NR4A2 ( [172] ; see also [173] ). These findings allowed us to discover a second critical molecular sensor of GPER action beyond c-fos, namely CTGF, as highlighted in several subsequent studies (reviewed in [174] ).
Thereafter, we sought to determine the role of GPER in estrogen-mediated function with respect to the main components of the tumor microenvironment, cancer-associated fibroblasts (CAFs), which drive crucial malignant features such as invasion, metastasis and angiogenesis [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] . In a recent study [175] , we found that ligand-activated GPER generates a feedforward loop coupling IL1β induction by CAFs to IL1R1 expression by cancer cells, thereby promoting the up-regulation of IL1β/IL1R1 target genes, namely PTGES, COX2, RAGE and ABCG2. As a biological counterpart, the functional liaison between these two cell types triggered migration and invasive features in breast cancer cells, including fibroblastoid cytoarchitecture and F-actin reorganization. These data therefore contributed to the further appreciation of the role elicited by GPER toward pro-tumorigenic inflammatory phenotypes. In addition, we discovered that low oxygen tension, a critical factor in the hypoxic tumor environment, triggers, through HIF-1α, the induction of both GPER and its downstream target CTGF [176] . Similarly, it was remarkable to discover that GPER-mediated signaling upregulates HIF1α and VEGF, further supporting the involvement of GPER in cancer angiogenesis [177, 178] .
As previous studies had attempted to determine whether GPER may be considered a prognostic factor in cancer outcome/survival [179, 180] , a better understanding of its regulation was warranted. In this regard, our early as well as more recent studies have provided notable data regarding the potential of diverse growth factors and cognate receptors to modulate GPER, engaging its downstream signaling towards the stimulation of aggressive cancer features [181] [182] [183] [184] [185] [186] [187] [188] . Such studies gave us the opportunity to establish a great collaboration with Antonino Belfiore at the University of Catanzaro, Italy, to examine the molecular signals linking the insulin-like growth factor-I (IGF-I)/IGF-I receptor (IGF-IR) system and GPER, providing further insights on the well-established actions played by the IGF axis in cancer. Over the years, our studies of the actions of estrogen through GPER support the critical roles played by several other members of the GPCR family in cancer development and progression [189] . Last but not least, I must acknowledge the fundamental role played by the many young people who contributed to the aforementioned research topics, some of which are still members of our group, whereas others are working abroad.
Concluding thoughts on future research: the next 20 years
The history of estrogen has been replete with astounding discoveries and advances in medical care. Its critical roles in reproduction/fertility/menopause and breast cancer have resulted in perhaps some of the most transformative clinical advances of our time, namely the induction/prevention of conception (birth control), the alleviation of post-menopausal symptoms and diseases (menopausal hormone therapy), and the treatment of ER-positive breast cancer [27, 190] . Together, modulating the (patho)physiology of estrogen and its receptors has benefitted hundreds of millions of women. Despite our growing knowledge of the mechanisms of estrogen action, much remains to be understood. Although some of the first actions of estrogen to be described would today be defined as rapid or non-genomic, subsequent decades or work focused on the transcriptional or genomic actions of estrogen, before a resurgence of investigations into rapid effects in the 1990s and 2000s. Today, it is clear that the combined rapid and genomic effects of estrogen are critical to its overall function, and that even in the absence of estrogen (i.e. in the unliganded state), "classical" estrogen receptors [191] and GPER [162] exert constitutive (i.e. ligand-independent) functions on physiology and disease [192, 193] . However, these interactions are complex and involve multiple receptor types, both soluble and membrane associated. The development of selective ligands that either activate or inhibit individual receptors not only further our basic understanding of estrogen biology but may also represent important clinical opportunities for drug development [142, 146, 194, 195] . In the next 20 years, much remains to be elucidated regarding the actions of GPER and the possibility of diagnostics and therapeutics targeting the pathways that are regulated by this receptor.
In Memoriam: Oliver Smithies
As the authors were finalizing this manuscript, they learned of the death of Oliver Smithies (1925-2017) on January 10 [196, 197] . Smithies, like Mario Capecchi and Sir Martin Evans, had pioneered the generation of transgenic animals using embryonic stem cells [198, 199] , for which they received the 2007 Nobel Prize in Physiology or Medicine [200] . The technology introduced by Smithies was essential for studying the role of GPER in physiology and disease, as it was used to generate the first GPERdeficient mouse in 2007 [69, 70, 131, 162, 201] .
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